UNSPSC 51161519: Carmoterol

This classification denotes an antiasthmatic drug with the molecular formula C21H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9810NUL4D1, chemically known as 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one but generally known as carmoterol, which bears US NIH Compound Identifier 63952. European Medicines Agency schedules Aarmoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25400.

The term CARMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53.). Most nations schedule carmoterol under HS 29337900 and SITC 51561. As of Q4 2014, CARMOTEROL remains the US FDA Preferred Term for this commodity. SMILES: CC(CC1=CC=C(C=C1)OC)NCC(C2=C3C=CC(=O)NC3=C(C=C2)O)O.

UNSPSC 51161519 Carmoterol, a Commodity code, names a long-acting beta-2 agonist inhaled bronchodilator pharmaceutical commonly procured by state and local health departments, Medicaid agencies, public health clinics, and correctional facilities as part of chronic obstructive pulmonary disease and asthma treatment protocols. The code reflects procurement of the active pharmaceutical ingredient or finished formulation in bulk quantities for inventory or distribution to covered populations.

The source provides no recent state or local contract opportunities tagged to this code, which suggests limited current solicitation activity under the Commodity designation at the state and local level. Carmoterol procurement typically flows through established pharmaceutical supply contracts, state Medicaid formulary agreements, or national cooperative purchasing vehicles rather than discrete RFP or IFB cycles. Verification of active opportunities would require direct outreach to state Medicaid procurement offices, public health departments, or correctional health services in target states.